Glucagon-like Peptide-1 Receptor Agonists versus Sodium-Glucose Cotransporter Inhibitors for Treatment of T2DM

CONTEXT: Cardiovascular outcome trials (CVOT) of glucagon-like peptide-1 receptor agonists (GLP-1 RA) and sodium-glucose cotransporter 2 inhibitors (SGLT2i) demonstrated reduction of major adverse cardiovascular events (MACE), cardiovascular deaths (CVD), and renal outcomes. OBJECTIVE: Assist in the...

Descripción completa

Detalles Bibliográficos
Autores principales: McKee, Alexis, Al-Khazaali, Ali, Albert, Stewart G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Meta-Analysis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7182131/
https://www.ncbi.nlm.nih.gov/pubmed/32342023
http://dx.doi.org/10.1210/jendso/bvaa037

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7182131/
https://www.ncbi.nlm.nih.gov/pubmed/32342023
http://dx.doi.org/10.1210/jendso/bvaa037

Ejemplares similares